BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 8662951)

  • 21. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
    Stepanova V; Mukhina S; Köhler E; Resink TJ; Erne P; Tkachuk VA
    Mol Cell Biochem; 1999 May; 195(1-2):199-206. PubMed ID: 10395084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation.
    Ellis V; Danø K
    J Biol Chem; 1993 Mar; 268(7):4806-13. PubMed ID: 8444857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87).
    Longstaff C; Merton RE; Fabregas P; Felez J
    Blood; 1999 Jun; 93(11):3839-46. PubMed ID: 10339491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
    Høyer-Hansen G; Rønne E; Solberg H; Behrendt N; Ploug M; Lund LR; Ellis V; Danø K
    J Biol Chem; 1992 Sep; 267(25):18224-9. PubMed ID: 1381366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells.
    Ploug M; Rahbek-Nielsen H; Nielsen PF; Roepstorff P; Dano K
    J Biol Chem; 1998 May; 273(22):13933-43. PubMed ID: 9593742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
    Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
    Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion.
    Bonavaud S; Charrière-Bertrand C; Rey C; Leibovitch MP; Pedersen N; Frisdal E; Planus E; Blasi F; Gherardi R; Barlovatz-Meimon G
    J Cell Sci; 1997 May; 110 ( Pt 9)():1083-9. PubMed ID: 9175704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
    Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
    Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
    Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun TC; Appella E; Danø K; Blasi F
    J Biol Chem; 1992 May; 267(13):9129-33. PubMed ID: 1315748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
    Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE; Saunders DN; Ranson M
    Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.
    Conese M; Blasi F
    Biol Chem Hoppe Seyler; 1995 Mar; 376(3):143-55. PubMed ID: 7612191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
    Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
    Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.
    Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M
    J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
    Ploug M
    Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils.
    Plesner T; Ploug M; Ellis V; Rønne E; Høyer-Hansen G; Wittrup M; Pedersen TL; Tscherning T; Danø K; Hansen NE
    Blood; 1994 Feb; 83(3):808-15. PubMed ID: 8298141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
    Le DM; Besson A; Fogg DK; Choi KS; Waisman DM; Goodyer CG; Rewcastle B; Yong VW
    J Neurosci; 2003 May; 23(10):4034-43. PubMed ID: 12764090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
    Høyer-Hansen G; Pessara U; Holm A; Pass J; Weidle U; Danø K; Behrendt N
    Biochem J; 2001 Sep; 358(Pt 3):673-9. PubMed ID: 11535128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.